Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Rating) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 57,600 shares, a decline of 26.9% from the July 15th total of 78,800 shares. Based on an average trading volume of 2,800 shares, the short-interest ratio is presently 20.6 days.

Antibe Therapeutics Stock Performance

Shares of OTCMKTS ATBPF opened at $0.50 on Friday. The company has a market cap of $25.97 million, a P/E ratio of -1.19 and a beta of 0.32. The firm's fifty day moving average is $0.48 and its two-hundred day moving average is $0.54. Antibe Therapeutics has a 52-week low of $0.42 and a 52-week high of $1.11.

Analysts Set New Price Targets

Separately, Brookline Capital Management reiterated a "buy" rating on shares of Antibe Therapeutics in a report on Thursday, June 30th.

About Antibe Therapeutics

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

Featured Articles

• Get a free copy of the StockNews.com research report on Antibe Therapeutics (ATBPF)
• MarketBeat: Week in Review 8/8 – 8/12
• 2 Important Retail Stock Battles to Watch
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.